Urgent.News

One page, thousands of outlets. See who else covered it.

Editions

Health & Medicine

Moderna’s cancer shot: exciting for investors, inconclusive for patients

A glimmer of hope for sufferers, a potential revenue platform for a cash-burner, and a whole heap of unknowns

Moderna’s cancer shot: exciting for investors, inconclusive for patients

We haven't written up this one. Financial Times has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Read the original at ft.com →

More in Health & Medicine

Moderna shares soar 135% in a day after cancer vaccine succeeds in late-stage trial

Moderna shares surged after its personalized mRNA cancer vaccine trial showed positive results. The treatment, combined with Keytruda, reduced melanoma recurrence and spread significantly.

  • Moderna's shares surged 135% to $148.02 after cancer vaccine trial success
  • Intismeran vaccine combined with Merck's Keytruda showed reduced melanoma recurrence
  • Merck's shares rose 11% to $150.14, indicating potential growth for both companies

More from Wednesday 19 August →